Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum days the report can be obtained for the test Combined Screening with PlGF- Roche (SSDW):

  • Standard Report: 5-7 business days
  • Rush Report: 2-3 business days
  • Express Report: 1 business day

What are the prerequisites for the test Combined Screening with PlGF- Roche (SSDW)

  • Patients must be pregnant between 9 weeks and 13 weeks + 6 days gestation.
  • The patient's age and weight must be provided.
  • Patients must provide information on previous pregnancies, including any history of pre-eclampsia, miscarriage, or stillbirth.
  • Patients must not have any known fetal anomalies.
  • Patients must not have any medical conditions that may affect PlGF levels, such as chronic hypertension or renal disease.

What are the measure values for the test Combined Screening with PlGF- Roche (SSDW)

  • PlGF (pg/mL): 50-100
  • MoM: 0.5-2.0
  • SS: 1:50

What does this test Combined Screening with PlGF- Roche (SSDW) identify?

  • Test Name: Combined Screening with PlGF- Roche (SSDW)
  • Identifies: This test is used to identify the risk of developing pre-eclampsia in pregnant women. Pre-eclampsia is a serious condition that can occur during pregnancy and is characterized by high blood pressure and damage to organs, most commonly the liver and kidneys.
  • Methodology: The test measures the levels of Placental Growth Factor (PlGF) in the blood of pregnant women. Low levels of PlGF are associated with an increased risk of pre-eclampsia.
  • Significance: By identifying pregnant women at high risk for pre-eclampsia, healthcare providers can take preventive measures to monitor and manage the condition, reducing the risk of complications for both the mother and the baby.

Why is this test Combined Screening with PlGF- Roche (SSDW) taken?

  • Test Name: Combined Screening with PlGF- Roche (SSDW)
  • Purpose: This test is taken to assess the risk of developing pre-eclampsia in pregnant women.
  • Details: Pre-eclampsia is a serious condition that can occur during pregnancy, characterized by high blood pressure and damage to other organs, most commonly the liver and kidneys. This test combines the measurement of Placental Growth Factor (PlGF) levels with other markers to provide a more accurate assessment of the risk of pre-eclampsia. Early detection and monitoring of pre-eclampsia can help in timely intervention and management to ensure the health and safety of both the mother and the baby.

No FAQs available.

Customer Google Rating